Loading...

Collin Blakely, MD, PhD

TitleAssistant Professor
InstitutionUniversity of California San Francisco
DepartmentMedicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of WashingtonB.S.1997Molecular and Cellular Biology
    University of PennsylvaniaPh.D.2006Cell and Molecular Biology
    University of PennsylvaniaM.D.2007Medicine
    University of Pennsylvania Health SystemResidency2009Internal Medicine
    UCSFFellowship2011Medical Oncology
    Collapse Awards and Honors
    Damon Runyon Cancer Research Foundation2018  - 2021Damon Runyon Clinical Investigator Award
    AACR2014  - 2016AACR BioOncology Fellowship
    Uniting Against Lung Cancer2014  - 2016Legacy Award
    Bonnie J. Addario Lung Cancer Foundation2013Research Grant

    Collapse Overview 
    Collapse Overview
    Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-, and ALK-targeted therapies, and identifying new targets for molecular-directed therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.


    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. McCoach CE, Blakely C, Banks KC, Levy B, Chue BM, Raymond VM, Le A, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res. 2018 Mar 29. PMID: 29599410.
      View in: PubMed
    2. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 Jan 17; 29(1):96-103. PMID: 29125731.
      View in: PubMed
    3. Blakely C, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    4. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely C, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 Jan; 19(1):58-64. PMID: 28645632.
      View in: PubMed
    5. Jonsson VD, Blakely C, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 Mar 13; 7:44206. PMID: 28287179.
      View in: PubMed
    6. Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely C, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 01; 49(1):87-96. PMID: 27869830.
      View in: PubMed
    7. McCoach CE, Bivona TG, Blakely C, Doebele RC. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 Sep; 17(5):466-469. PMID: 27378174.
      View in: PubMed
    8. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely C, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. PMID: 26301689; PMCID: PMC4734742.
    9. Blakely C, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-?B-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. PMID: 25843712; PMCID: PMC4394036.
    10. Blakely C, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5. PMID: 23071030; PMCID: PMC3475614.
    11. Blakely C, Jahan T. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011 Oct; 11(10):1607-18. PMID: 21999134.
      View in: PubMed
    12. Blakely C, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res. 2006 Jun 15; 66(12):6421-31. PMID: 16778221.
      View in: PubMed
    13. Blakely C, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA. Developmental stage determines the effects of MYC in the mammary epithelium. Development. 2005 Mar; 132(5):1147-60. PMID: 15689376.
      View in: PubMed
    14. Gale M, Blakely C, Darveau A, Romano PR, Korth MJ, Katze MG. P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress. Biochemistry. 2002 Oct 01; 41(39):11878-87. PMID: 12269832.
      View in: PubMed
    15. Tan SL, Tareen SU, Melville MW, Blakely C, Katze MG. The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation. J Biol Chem. 2002 Sep 27; 277(39):36109-17. PMID: 12138106.
      View in: PubMed